One of them is CRISPR Therapeutics ( CRSP -0.90%). It has an approved gene-editing therapy, but investors haven't been buying ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

That's only about 6 times next year's revenue estimates, and sales should continue to grow, since CRISPR Therapeutics and Vertex Pharmaceuticals have just started rolling out Casgevy. Even better ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals (NASDAQ: VRTX) on Casgevy. Although Vertex takes a larger share of profit at 60%, this is worthwhile because Vertex has the ...

CRISPR Therapeutics' stock is down 20% since ... To be blunt, CRISPR’s cash position and strategic collaboration with Vertex Pharmaceuticals (VRTX) are its only “saving grace” at this ...

Biopharmas have been scaling back on AAV research for sometime now. Find out why and what's on the horizon for drug delivery ...

CRISPR Therapeutics has not performed well in the past year and a half since hitting that milestone. Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won ...

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company ...

Vertex Pharmaceuticals is amending its collaboration with CRISPR Therapeutics, paying $900 million now for chance to grab a bigger share of a gene-editing therapy’s profits later---if the ...